Clinical Trial Update: EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the EP1300 polyepitope DNA vaccine for Plasmodium falciparum malaria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• EP1300 polyepitope DNA vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Plasmodium Falciparum Malaria | Phase 1 | Status: COMPLETED